Press release
Cutaneous lupus erythematosus Market: Epidemiology, Therapies, Companies, DelveInsight | Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth The
Cutaneous lupus erythematosus Market
Therapies for cutaneous lupus erythematosus, including Litifilimab, Daxdilimab, and others, are anticipated to drive growth in the cutaneous lupus erythematosus market in the coming years.
DelveInsight has launched a new report on "Cutaneous lupus erythematosus - Market Insights, Epidemiology, and Market Forecast-2034 [https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" that delivers an in-depth understanding of the Cutaneous lupus erythematosus, historical and forecasted epidemiology as well as the Cutaneous lupus erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover more about the cutaneous lupus erythematosus disease, diagnosis, treatment options @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Some of the key facts of the Cutaneous lupus erythematosus Market Report:
*
The Cutaneous Lupus Erythematosus (CLE) market across the 7MM was valued at nearly USD 500 million in 2023. CLE, a chronic autoimmune skin disorder, accounts for about 10% of all lupus cases. The United States reports the highest prevalence with roughly 500,000 diagnosed cases, followed by the EU4, the UK, and Japan. Women represent the majority of patients (~64%) compared to men (~36%).
*
Around 70% of diagnosed patients receive treatment, often involving a mix of topical and systemic therapies depending on disease severity. More than 30% present with moderate-to-severe disease, requiring biologics and systemic immunomodulators alongside standard care. Currently, only hydroxychloroquine and glucocorticoids are FDA-approved for CLE.
*
Emerging drug classes-including BDCA2 protein inhibitors, dendritic cell inhibitors, and TYK2 kinase inhibitors-are set to broaden treatment options. Biogen's litifilimab and Bristol Myers Squibb's deucravacitinib are projected to dominate the market during 2024-2034, each expected to capture around 25% of sales. Other key players, such as Horizon Therapeutics, Gilead Sciences, and Merck KGaA, are advancing pipeline therapies. Horizon, for instance, began a Phase II trial in January 2023 for moderate-to-severe discoid lupus erythematosus.
*
In 2023, there were about 800,000 diagnosed prevalent CLE cases across the 7MM, a figure expected to increase over time. Research suggests that nearly two-thirds of lupus patients experience skin involvement, with about 2% of systemic lupus erythematosus (SLE) cases progressing to CLE annually.
*
Recent trial results highlight progress: Biogen's litifilimab showed significant disease activity reduction in Phase II results (October 2023), while Bristol Myers Squibb's deucravacitinib demonstrated marked symptom improvement in April 2024. Beyond physical symptoms, a Medscape survey (April 2024) emphasized CLE's impact on mental health, social well-being, and financial stability.
*
Leading companies in the CLE space include Biogen, Bristol Myers Squibb, Horizon Therapeutics, Gilead Sciences, Daiichi Sankyo, EMD Serono, Sanofi, Merck KGaA, Kyowa Kirin, Priothera, Centessa Pharmaceuticals, Hoth Therapeutics, and Zylo Therapeutics. Promising therapies under development feature Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran, among others.
Key benefits of the Cutaneous lupus erythematosus market report:
*
Cutaneous lupus erythematosus market report covers a descriptive overview and comprehensive insight of the Cutaneous lupus erythematosus Epidemiology and Cutaneous lupus erythematosus market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
*
The Cutaneous lupus erythematosus market report provides insights on the current and emerging therapies.
*
Cutaneous lupus erythematosus market report provides a global historical and forecasted market covering drug outreach in 7MM.
*
The Cutaneous lupus erythematosus market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cutaneous lupus erythematosus market.
Got queries? Click here to know more about the Cutaneous lupus erythematosus Market Landscape https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cutaneous lupus erythematosus Overview
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune condition that specifically targets the skin and belongs to the broader lupus erythematosus spectrum, where symptoms remain limited to the skin. In contrast, Lupus Erythematosus (LE) is a systemic autoimmune disorder that can affect multiple organs and present with diverse symptoms. CLE is categorized into three main types: acute cutaneous lupus erythematosus (ACLE), subacute CLE, and chronic CLE (CCLE). The chronic form includes subtypes such as discoid LE (DLE), LE profundus (LEP), chilblain LE (CHLE), and LE tumidus (LET). Diagnosis typically requires identifying the exact subtype using clinical examination, lab investigations, histopathology, antibody testing, and, in some cases, direct immunofluorescence-while also excluding systemic involvement.
Cutaneous lupus erythematosus Market Outlook
The Cutaneous Lupus Erythematosus market is expected to undergo significant shifts in the coming years, driven by the anticipated launch of emerging therapies from leading companies such as Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, EMD Serono, Hoth Therapeutics, Zylo Therapeutics, Sanofi, Merck KGaA, Kyowa Kirin, Priothera, Centessa Pharmaceuticals, and others throughout the 2020-2034 forecast period.
Explore how the cutaneous lupus erythematosus market is rising in the upcoming years @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cutaneous lupus erythematosus Emerging Drugs
*
Litifilimab: Biogen
*
Daxdilimab: Horizon Therapeutics/ Amgen
Scope of the Cutaneous lupus erythematosus Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Cutaneous lupus erythematosus Companies: Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth Therapeutics, Zylo Therapeutics, Sanofi, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, and others
*
Key Cutaneous lupus erythematosus Therapies: Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran, and others
*
Cutaneous lupus erythematosus Therapeutic Assessment: Cutaneous lupus erythematosus current marketed and Cutaneous lupus erythematosus emerging therapies
*
Cutaneous lupus erythematosus Market Dynamics: Cutaneous lupus erythematosus market drivers and Cutaneous lupus erythematosus market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Cutaneous lupus erythematosus Unmet Needs, KOL's views, Analyst's views, Cutaneous lupus erythematosus Market Access and Reimbursement
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Cutaneous lupus erythematosus Patient Share (%) Overview at a Glance
5. Cutaneous lupus erythematosus Market Overview at a Glance
6. Cutaneous lupus erythematosus Disease Background and Overview
7. Cutaneous lupus erythematosus Epidemiology and Patient Population
8. Country-Specific Patient Population of Cutaneous lupus erythematosus
9. Cutaneous lupus erythematosus Current Treatment and Medical Practices
10. Unmet Needs
11. Cutaneous lupus erythematosus Emerging Therapies
12. Cutaneous lupus erythematosus Market Outlook
13. Country-Wise Cutaneous lupus erythematosus Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Cutaneous lupus erythematosus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Cutaneous lupus erythematosus Market Outlook 2034 https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Related Reports:
Cutaneous lupus erythematosus Pipeline Insights, DelveInsight
"Cutaneous lupus erythematosus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cutaneous lupus erythematosus market. A detailed picture of the Cutaneous lupus erythematosus pipeline landscape is provided, which includes the disease overview and Cutaneous lupus erythematosus treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cutaneous-lupus-erythematosus-market-epidemiology-therapies-companies-delveinsight-biogen-horizon-therapeutics-bristolmyers-squibb-gilead-sciences-daiichi-sankyo-inc-emd-serono-hoth-the]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cutaneous lupus erythematosus Market: Epidemiology, Therapies, Companies, DelveInsight | Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth The here
News-ID: 4176533 • Views: …
More Releases from ABNewswire
Rhinitis Pipeline 2025: Innovative Clinical Breakthroughs Led by 35+ Global Lead …
DelveInsight's, "Rhinitis - Pipeline Insight, 2025," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Rhinitis companies are Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene…
ANCA Vasculitis Pipeline 2025: Pioneering Clinical Progress Driven by 12+ Global …
DelveInsight's, "ANCA Vasculitis - Pipeline Insight, 2025," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The ANCA vasculitis (anti-neutrophil cytoplasmic antibody-associated vasculitis) market, a rare…
Autoimmune uveitis Market: Epidemiology, Therapies, Companies, DelveInsight | Ta …
The Autoimmune Uveitis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Autoimmune Uveitis market size from 2020 to 2034. The Autoimmune Uveitis market report also covers current Autoimmune Uveitis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Autoimmune Uveitis market.
Therapies for autoimmune uveitis, including YUTIQ, HUMIRA (Adalimumab), TRS01,…
Inflammatory Myositis Market: Epidemiology, Therapies, Companies, DelveInsight | …
Inflammatory myositis market report provides current treatment practices, emerging drug, market size and market share of the individual therapies, current and forecasted 7MM from 2020 to 2034. The report also covers current inflammatory myositis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Emerging therapies for inflammatory myositis, including Dazukibart (PF-06823859) and others, are anticipated to drive growth in…
More Releases for Cutaneous
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Cutaneous Angiosarcoma Market New Product Development & Latest Trends
Introduction
Cutaneous angiosarcoma is a rare and aggressive malignancy that originates from endothelial cells lining blood vessels and lymphatics in the skin. Though it represents a small fraction of soft-tissue sarcomas, its high recurrence rates, metastatic potential, and poor prognosis make it one of the most challenging cancers to manage. The condition most frequently affects elderly patients and is often associated with chronic lymphedema, prior radiation exposure, or immunosuppression.
Traditional management has…
Emerging Trends Influencing The Growth Of The Cutaneous T-Cell Lymphoma Market: …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Cutaneous T-Cell Lymphoma Market Size Expected to Be by 2034?
The market for cutaneous T-cell lymphoma has witnessed substantial growth in the past few years. It is projected to rise from a size of $2.54 billion in 2024 to $2.72 billion in 2025, equating to a compound annual…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Key Trend Reshaping the Cutaneous Lupus Erythematosus Market in 2025: Advancemen …
What Are the Projections for the Size and Growth Rate of the Cutaneous Lupus Erythematosus Market?
The market size for cutaneous lupus erythematosus has seen quick expansion in the past few years. The growth is estimated to move from $2.24 billion in 2024 to $2.51 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.0%. This considerable increase in the historic period is a result of factors such as…
Cutaneous Lupus Erythematosus Market Trends & Analysis Report 2024
"The Business Research Company recently released a comprehensive report on the Global Cutaneous Lupus Erythematosus Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
